Fluorouracil

• 产品号: DB00544
• CAS号: 51-21-8
• 分子式: C4H3FN2O2
• 分子量: 130.0772232

产品别名

• 标题: Fluorouracil
• IUPAC标准名: 5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
• IUPAC传统名: fluorouracil
• 商标名: 5 Fluorouracil; Phtoruracil; Effluderm; Queroplex; Adrucil; Carzonal; Efudex; Efudix; Efurix; FU; Fluoroblastin; Fluri; Fluro Uracil; Timazin; URF; Ulup; Arumel; Carac; Fluoroplex; Fluracil; Fluracilum; Fluril; Ftoruracil; Kecimeton; Phthoruracil

产品登记号

• PubChem SID: 46508557
• CAS号: 51-21-8
• PubChem CID: 3385

产品性质

• 疏水性(logP): -0.8
• 溶解度: < 0.1 g/100 mL at 19 °C

产品详细信息

详细说明 (English)

• Drug Groups: approved
• Description: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
• Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
• Pharmacology: Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.
• Toxicity: LD₅₀=230mg/kg (orally in mice)
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: 28-100%
• Half Life: 10-20 minutes
• Protein Binding: 8-12%
• Elimination: Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour.; The remaining percentage of the administered dose is metabolized, primarily in the liver.
• References: Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. [Pubmed] ; Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8. Pubmed
• Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204. Pubmed